John J. Gormally is CEO at Akers Biosciences, Inc. (AKER). They have made 1 open-market trade across 1 company since 2016, most recently 2017-10-17.
CIK 0001661118
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $6K since 2016, never a sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| AKER | 30,000 | $148K |
Shares reported on the most recent Form 4, priced at the 2018-04-10 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| AKER | BUY | 2016-05-24 | 2016-05-24 | $2.23 | $6K | -18.3% | -10.7% | +42.9% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.